文献速递脊柱关节炎

表面活性蛋白D可能是中轴型脊柱关节炎炎症的潜在介质

Surfactant protein-D, a potential mediator of inflammation in axial spondyloarthritis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

研究纳入34例未使用病情改善药物的中轴型脊柱关节炎(axSpA)患者,检测血清SP-D水平及分子大小分布,并与健康对照比较。axSpA患者与对照的血清SP-D水平无显著差异,但校正Met11Thr多态性、性别、年龄、BMI和吸烟后,axSpA患者SP-D的高分子量/低分子量比值显著低于对照,作者认为低分子量寡聚体变异型SP-D占优势可能增强axSpA的局部或全身炎症反应。

要点

  • axSpA患者与健康对照血清SP-D水平无显著差异,且SP-D与疾病活动度不相关。
  • 校正Met11Thr多态性、性别、年龄、BMI和吸烟后,axSpA患者SP-D高分子量/低分子量比值显著低于对照。
  • SP-D高分子量/低分子量比值与CRP或复合疾病结局指标无相关性。

核心结论

  • 作者认为低分子量寡聚体变异型SP-D占优势可能增强axSpA的局部或全身炎症反应。

研究设计与样本

  • 研究纳入34例符合ASAS标准、未使用病情改善药物的axSpA患者,年龄19-63岁,病程3.9(2.2-5.6)年。
  • 记录人口学、吸烟习惯、HLA-B27状态、ASDAS、BASDAI、BASFI、BASMI和视觉模拟量表评分。
  • 采用ELISA检测血清SP-D,全血提取DNA并对单核苷酸多态性rs721917进行基因分型,凝胶过滤色谱法测定SP-D分子大小分布。

主要发现

  • axSpA患者与健康对照血清SP-D水平无显著差异,1177(869,1536)vs 910(494,1682)(P = 0.35)。
  • 血清SP-D与疾病活动度不相关。
  • 校正Met11Thr多态性、性别、年龄、BMI和吸烟后,axSpA患者血清SP-D高分子量/低分子量比值显著低于对照,0.38(0.18,0.53)vs 1.49(0.37,3.24)(P = 0.0004)。
  • 高分子量/低分子量比值与CRP或复合疾病结局指标无相关性。

关键数值与推荐

  • axSpA患者血清SP-D为1177(869,1536),健康对照为910(494,1682),组间比较P = 0.35。
  • 校正Met11Thr多态性、性别、年龄、BMI和吸烟后,axSpA患者SP-D高分子量/低分子量比值为0.38(0.18,0.53),对照为1.49(0.37,3.24),P = 0.0004。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Surfactant protein-D (SP-D), an innate immune defence molecule of the collectin family, is expressed in lungs and additional extrapulmonary epithelia. SP-D has immune modulatory and anti-microbial effects depending on its oligomerization. The ratio of high molecular weight (HMW): low molecular weight (LMW) SP-D in serum is mainly determined by the Met11Thr polymorphism (SNP rs721917). We aimed to study the SP-D serum level and the molecular size distribution in patients with untreated axial spondyloarthritis (axSpA) as compared with control subjects. METHODS: Thirty-four patients with disease modifier untreated axSpA according to the ASAS criteria, age 19-63 years, disease duration 3.9 (2.2-5.6) years were included. Demographics, smoking habits, HLA-B27 status, ASDAS, BASDAI, BASFI, BASMI and visual analogue scale scores were recorded. SP-D in serum was measured by ELISA. DNA was isolated from whole blood and single nucleotide polymorphism rs721917 was genotyped. SP-D molecular size distribution was determined using gel filtration chromatography. RESULTS: SP-D in serum did not differ between patients with axSpA and healthy controls, 1177 (869, 1536) vs 910 (494, 1682) (P = 0.35) and SP-D did not correlate with disease activity. However, the HMW/LMW ratio of SP-D in serum was significantly lower in axSpA, 0.38 (0.18, 0.53) compared with controls 1.49 (0.37, 3.24) when adjusting for the Met11Thr polymorphism, gender, age, BMI and smoking (P = 0.0004). There was no correlation between HMW/LMW ratio and CRP or composite diseases outcome measures. CONCLUSION: We suggest that predominance of LMW oligomeric variants of SP-D may enhance local or systemic inflammatory responses in axSpA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Munk HL, Fakih D, Christiansen L, et al. Surfactant protein-D, a potential mediator of inflammation in axial spondyloarthritis. Rheumatology (Oxford). 2018. PMID: 29982797. doi:10.1093/rheumatology/key187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。